Figure 3From: Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration – evaluation in a clinical setting Change in mean retinal thickness (μm) of reduced responders (black) and responders (white) at baseline (month 0) and after the first three consecutive injections (month 4) to the end of follow-up (month 6). Back to article page